(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 2.08% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.44%.
Amgen's revenue in 2024 is $32,534,000,000.On average, 11 Wall Street analysts forecast AMGN's revenue for 2024 to be $17,831,653,649,987, with the lowest AMGN revenue forecast at $17,678,376,194,024, and the highest AMGN revenue forecast at $17,983,157,247,965. On average, 11 Wall Street analysts forecast AMGN's revenue for 2025 to be $18,313,141,061,157, with the lowest AMGN revenue forecast at $17,289,740,035,295, and the highest AMGN revenue forecast at $19,160,565,161,695.
In 2026, AMGN is forecast to generate $18,556,798,731,633 in revenue, with the lowest revenue forecast at $17,470,136,017,134 and the highest revenue forecast at $19,252,854,692,440.